Biosimilars Could Save Big Businesses Billions Of Dollars

By 2025, biosimilars are expected to save the US health-care system up to $183 billion.

 

By promoting the use of biosimilars in employer-sponsored health plans in 2018, all self-insured firms in the United States might have saved $1.4 billion and generated significant savings for their employees.

Biosimilars have enormous potential, yet many organizations are still losing out on millions of dollars in savings. Employers should consider biosimilars as a viable solution to lower health expenditures and realize significant savings for their employees, with nearly half of Americans relying on their or their family’s employer for health coverage, and as the costs of care in the US rise, employers should consider biosimilars as a viable solution to lower health expenditures and realize significant savings for their employees. Employers can help to ensure the health system’s long-term viability and accessibility by doing so.

 

Employers around the United States are now reaping the benefits of biosimilar replacement plans. Ford Motor Company, for example, recently published a case study on their method for incorporating biosimilars into their health plan, which required new and existing users of a reference product to switch to the biosimilar. Ford has saved roughly $5 million since the shift began in 2019. As a result, we’re starting to see more Michigan employers establish comparable schemes with no disruption to members, ensuring that patients get the treatment they need at a lower cost. This case study serves as a model for other employers around the United States who are seeking for cost-effective strategies to minimize overall health-care spending and employee out-of-pocket costs.

 

As the promise of biosimilars continues to be realized in the United States, more patients—an estimated 1.2 million by 2025—will be able to benefit from these high-quality, more affordable biologic medications. By 2025, biosimilars are expected to save the US health-care system up to $183 billion.

In the United States, there are now 33 approved biosimilars and 21 commercialized biosimilars in oncology, ophthalmology, immunology, and diabetes, with more on the way. 2023 will be a watershed year for biosimilars, with a number of new medications set to launch that will have a big impact for patients across new disease areas. Employers will have a critical chance to work with payers and PBMs to ensure biosimilars are included on formularies. Additional training will be necessary to ensure that both employers and employees recognize the benefit that these more cost, high-quality, safe, and effective biologic drugs can give.

 

Employers’ responsibilities

As organizations cooperate with PBMs and consultants to build benefit plans for next year, there are a few proactive steps they can take right now.

 

Pose inquiries. Prepare to grill medical carriers, PBMs, and consultants with difficult questions. For example, request member data, information about available programs, and where medical carriers are innovating on behalf of plan sponsors from medical carriers. Employers should hire a professional pharmaceutical consultant as well as a rebate aggregator.

 

Create a well-thought-out plan. When it comes to biosimilar adoption, this is crucial. Consider limited grandfathering to allow existing drugs to be used so that patients’ treatment cycles are not disrupted, and to guarantee clear communication with members. Employers should also avoid adopting a one-size-fits-all strategy. Consider designing a strategy for each drug, taking into account the drug’s market dynamics, physician acceptance, and treatment condition.

 

Employees should be educated. Employers can assist establish confidence and trust in biosimilar medicines by educating new and existing employees about their benefit packages. Biosimilar information and education, including possible cost reductions, real-time benefit lookup tools, and cost calculators that include biosimilars as an option, should be included in the company’s online and email communications.

 

Take a look at rebates. Rebates have a big impact on employer-sponsored health care, and they need to be addressed carefully. Employers should not be scared to pursue a plan based on the lowest net cost without rebates. If a rebate model is utilized, however, the rebates should be reevaluated on a frequent basis because the rebate landscape is continuously changing, and employers will need to change their strategy to assure the lowest net cost.

 

Realizing biosimilars’ full potential

Biosimilars are now more crucial than ever in generating cost savings and improving patient access. Acceptance and uptake of biosimilars is increasing, and the United States is well-positioned to welcome additional biosimilars in the coming years. However, more has to be done to guarantee that these drugs are successful and that their potential savings are completely realized. Employers can save millions of dollars and make biosimilars more accessible to patients across the United States by providing proper education and collaborating with payers.

 

 

 

 

Source: https://www.benefitspro.com/2022/04/20/promoting-biosimilars-could-save-large-employers-billions/